secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001493152-24-024430
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma reports CC-42344 active against avian H5N1 PB2; Phase 2a results expected H2 2024
--------------------------------------------------------------------------------

- In vitro studies show CC-42344 inhibits the PB2 protein of avian influenza A (H5N1) strain from infected dairy cattle.
- Phase 2a clinical trial of oral CC-42344 in influenza A subjects ongoing; topline results expected in second half of 2024.
- CC-42344 binds to highly conserved PB2 region; high barrier to resistance and broad-spectrum activity highlighted.
- CDC reports first human H5N1 cases from dairy cows; company notes no FDA-approved vaccine for humans against this strain.
- Positive Phase 1 safety/tolerability data reported in 2022; structure-based platform used to confirm binding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224024430/0001493152-24-024430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224024430/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-024430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer